Metastatic Lung Cancer - 2026 Update

Created using ChatSlide

This overview focuses on the 2026 landscape of metastatic lung cancer, emphasizing the need to diagnose and stratify patients by mapping the burden and survival rates of NSCLC and SCLC using NCI and SEER statistics. It highlights treatment advances by advocating for biomarker testing to tailor therapies, comparing immunotherapy, targeted therapies, and ADCs, and illustrating these concepts through patient cases. Additionally, it stresses the importance of personalizing clinical decisions with...